Abbott Laboratories (NYSE:ABT) Price Target Raised to $112.00

Posted by Stanley Muller on Jul 17th, 2026

Abbott Laboratories (NYSE:ABT – Get Free Report) had its price objective boosted by investment analysts at Citigroup from $108.00 to $112.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the healthcare product maker’s stock. Citigroup’s target price suggests a potential upside of 11.90% from the company’s previous close.

Other equities analysts have also recently issued reports about the stock. Weiss Ratings upgraded shares of Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, July 7th. Raymond James Financial reduced their price objective on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Robert W. Baird started coverage on Abbott Laboratories in a research note on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 target price on the stock. Benchmark dropped their target price on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Finally, The Goldman Sachs Group cut their price target on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research note on Wednesday, May 27th. Three analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $118.61.

Check Out Our Latest Research Report on Abbott Laboratories

Abbott Laboratories Stock Up 1.3%

Shares of NYSE ABT traded up $1.26 during mid-day trading on Friday, reaching $100.09. The company had a trading volume of 12,174,010 shares, compared to its average volume of 12,351,627. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The company has a market capitalization of $174.33 billion, a price-to-earnings ratio of 27.99, a PEG ratio of 1.54 and a beta of 0.61. The stock has a fifty day moving average of $89.56 and a two-hundred day moving average of $102.18. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49.

Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. The firm had revenue of $12.51 billion for the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm’s revenue was up 13.0% on a year-over-year basis. During the same period in the previous year, the firm posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities research analysts expect that Abbott Laboratories will post 5.48 EPS for the current year.

Insider Buying and Selling at Abbott Laboratories

In other news, Director Daniel J. Starks bought 10,000 shares of the business’s stock in a transaction on Monday, April 27th. The stock was purchased at an average price of $92.65 per share, with a total value of $926,500.00. Following the transaction, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Philip P. Boudreau purchased 2,200 shares of the stock in a transaction dated Thursday, April 23rd. The stock was acquired at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the transaction, the chief financial officer owned 2,200 shares of the company’s stock, valued at $201,300. The trade was a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is currently owned by corporate insiders.

Institutional Trading of Abbott Laboratories

Several hedge funds have recently added to or reduced their stakes in ABT. Vanguard Group Inc. increased its stake in shares of Abbott Laboratories by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock valued at $21,995,501,000 after buying an additional 2,402,408 shares in the last quarter. State Street Corp raised its stake in shares of Abbott Laboratories by 2.1% in the fourth quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker’s stock worth $10,004,880,000 after acquiring an additional 1,627,791 shares during the last quarter. Capital International Investors lifted its position in shares of Abbott Laboratories by 2.6% during the fourth quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker’s stock worth $7,922,519,000 after purchasing an additional 1,614,706 shares in the last quarter. J. Stern & Co. LLP lifted its position in shares of Abbott Laboratories by 12,439.6% during the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after purchasing an additional 39,005,451 shares in the last quarter. Finally, Capital Research Global Investors grew its stake in shares of Abbott Laboratories by 1.0% during the fourth quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker’s stock valued at $4,907,523,000 after purchasing an additional 400,400 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: JPMorgan raised its price target on Abbott to $120 and kept an overweight rating, signaling confidence in additional upside. JPMorgan raises Abbott price target
Positive Sentiment: Wells Fargo lifted its target to $112 and maintained an overweight rating, while TD Cowen and RBC also reiterated bullish calls, adding to the positive analyst tone. Analysts raise Abbott forecasts after Q2 results
Positive Sentiment: Abbott’s Q2 results topped expectations and the company raised full-year EPS guidance, with management highlighting stronger second-half demand across key businesses. Abbott reports Q2 2026 results and raises guidance
Positive Sentiment: Analysts and market commentary said the better-than-expected quarter eased concerns and helped the stock regain Wall Street confidence, with particular strength in medical devices and diagnostics. Abbott stock winning back Wall Street
Neutral Sentiment: Some articles noted that Abbott’s profit fell year over year in Q2 despite better sales, reflecting margin and mix changes rather than a clear operational setback. WSJ report on Abbott Q2

About Abbott Laboratories

(Get Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.